trending Market Intelligence /marketintelligence/en/news-insights/trending/v88a-c6t4vlr3_ftf4sv8w2 content esgSubNav
In This List

Sage Therapeutics drug receives US FDA breakthrough therapy designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sage Therapeutics drug receives US FDA breakthrough therapy designation

Sage Therapeutics Inc. said its experimental drug Sage-217 received the U.S. Food and Drug Administration's breakthrough therapy designation to treat depression.

The Cambridge, Mass.-based biotechnology company said the regulator's decision was primarily based on data from a phase 2 trial, which met its main goal.

The designation will help expedite development and regulatory review of the drug.

SAGE-217 is also being developed for Parkinson's disease and sleep disorders.